Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivors

描述(申请人提供)：加州大学有超过1200万癌症幸存者。癌症存活率和了解癌症治疗的远期效应是一个高度优先的领域。强大的SWOG临床试验数据库与联邦医疗保险索赔数据的联系为评估治疗的晚期效应提供了独特的机会，并可能建立一种机制，在临床试验后续行动结束后确定治疗组之间的结果差异。我们建议使用一个数据库，将参加SWOG临床治疗和预防试验的患者联系起来，在该数据库中，人口统计学、肿瘤细节、预后因素、临床因素、治疗类型(静脉、皮下和口服)和接受剂量、治疗期间的短期毒性、复发和生存结果的详细信息与Medicare索赔数据(基于ICD-9、HCPCS和CPT代码)一起收集，这些数据可以提供与治疗相关的潜在疾病、并存状况、新诊断、后续治疗、住院和成本/资源利用的长期跟踪。对于特定的目标 根据我们的提案，我们将使用SWOG-Medicare链接数据库来确定(A)前列腺癌患者随机分为连续雄激素剥夺组和间歇性雄激素剥夺组(B)接受和不接受雄激素剥夺治疗的前列腺癌患者(C)接受和不接受紫杉烷治疗的乳腺癌和前列腺癌患者(D)接受和不接受铂类药物治疗的非小细胞肺癌患者(E)接受化疗和放射治疗的骨盆癌患者(E)非小细胞肺癌患者(E)接受化疗和放射治疗的前列腺癌患者。对于每个子目标，我们将研究这些并发症如何随先前存在的并存疾病，如糖尿病和高血压，以及临床和人口因素而变化，并检查临床试验治疗期间根据共同毒性标准(CTC-AE)进行评估的短期毒性与长期毒性之间的关系。使用唯一和有价值的联邦医疗保险索赔数据库与西南肿瘤学集团的NCI临床试验数据库相结合，我们可以执行分析，以克服以前仅使用SEER-Medicare数据库进行的基于人群的研究的局限性。如果我们能够更好地预测谁是晚期毒性的最大风险，谁不是，我们就可以改善不断增长的癌症幸存者的长期结果。

DESCRIPTION (provided by applicant): There are over 12 million cancer survivors in the UC. Cancer survivorship and understanding late effects of cancer therapy is a high priority area. The linkage of the powerful SWOG clinical trial database to Medicare claims data provides a unique opportunity to evaluate late effects of therapy, and may establish a mechanism for identifying differences in outcomes between treatment groups after the clinical trial follow-up ends. We propose to use a database that has linked patients enrolled on SWOG clinical treatment and prevention trials where detailed information on demographics, tumor details, prognostic factors, clinical factors, treatment type (intravenous, subcutaneous and oral) and dose received, short term toxicities during the treatment period, recurrence and survival outcomes are captured with Medicare claims data (based on ICD-9, HCPCS, and CPT codes) which can provide long-term follow-up with underlying illnesses, comorbid conditions, new diagnoses, subsequent treatment, hospitalizations and costs/resource utilization associated with treatment. For the specific aims of our proposal, we will use the SWOG-Medicare linked database to determine the long term cardiovascular, hematologic, gastrointestinal, renal, endocrinologic and neurologic complications of (a) patients with prostate cancer randomized to continuous vs intermittent androgen deprivation (b) patients with prostate cancer treated with and without androgen deprivation (c) patients with breast and prostate cancer treated with and without taxanes (d) patients with non-small cell lung cancer treated with and without platinum agents (e) patients with pelvic cancer treated with chemotherapy and radiation vs. radiation alone. For each of these sub-aims, we will examine how these complications vary by pre-existing co-morbidities, such as diabetes and hypertension, as well as clinical and demographic factors, and examine the relationship between short term toxicities assessed during therapy on a clinical trial, as characterized by the Common Toxicity Criteria (CTC-AE), and long-term toxicities. Using the unique and valuable linked Medicare claims database with the NCI clinical trials database of the Southwest Oncology Group, we can perform analyses that overcome limitations of previously conduced population based research that utilized the SEER-Medicare database alone. If we can better predict who is at greatest risk for late toxicity, and who is not, we can improve long term outcomes for the growing population of cancer survivors